SPECT显像评价骨肿瘤治疗剂153Sm－EDTMP在骨转移灶的保留率

A Study of Retaining Percent age of Samarium-153-EDTMP in the Sites of Bone Metastases by SPECT Imaging

本文报道了用１５３Ｓｍ－ＥＤＴＭＰ治疗骨转移癌３２例，用ＳＰＥＣＴ显像法动态连续观察转移灶和正常骨胳各时相的保留率，发现骨转移灶和正常骨对１５３Ｓｍ－ＥＤＴＭＰ的清除在４８小时以前有显著性差异，而在４８小时以后无显著性差异。资料又证明骨转移癌病人的尿液和１５３Ｓｍ－ＥＤＴＭＰ原液纸层析测定其Ｒｆ值是完全相同的。表明１５３Ｓｍ－ＥＤＴＭＰ以骨中清除是以原形物的方式入血，入血的１５３Ｓｍ－ＥＤＴＭＰ又被代谢活跃的转移灶再摄取，结果致转移灶的放射性活度增加，而正常骨代谢低于转移灶，再摄取的量极少，因而两者在４８小时以前有差异，而４８小时以后清除到血中的量减少，再摄取减少。

patients with a variety of metastatic bone cancer were treated with 153 Sm-EDTMP The retaining percentage of metastatic lesions and normal bones was successively examined by SPECT imaging Our preliminary results indicated that the metastatic lesions and normal bones were significantly different in clearance rate of 153 Sm-EDTMP within 48h Furthermore, the Rf value of patient's urine and original 153 Sm-EDTMP liquid was entirely identical, that is to say, the matter cleared from skeleton to blood was 153 Sm-EDTMP itself 153 Sm-EDTMP cleared from normal bone and metastatic lesions was again absorbed by metabolically active metastatic lesions The redistribution leads to an increased radioactivity in metastatic lesions Since normal bone is not so metabolically active as that of metastatic lesions, little 153 Sm-EDTMP redistributed in normal bone There is a statistically significant difference in retaining percentage of 153 Sm-EDTMP between metastatic lesions and normal bone within 48h after injection of 153 Sm-EDTMP